InterShunt’s Pioneering Heart Failure Catheter
July 2024
InterShunt Technologies, Inc. is a medical device company focused on developing innovative solutions for heart failure. The company is pioneering a catheter-based technology aimed at reducing left atrial pressure in heart failure patients through a minimally invasive procedure.
Percutaneous Atrial Shunt Catheter
The core technology developed by InterShunt is the Percutaneous Atrial Shunt Catheter (PAS-C) system. This system is designed to create a shunt within the heart, allowing blood to flow more freely and reducing the pressure build-up that can lead to severe symptoms like pulmonary congestion and shortness of breath. Unlike other methods that require implants or energy to maintain the shunt, InterShunt’s device requires no such hardware, making it potentially safer and more effective.
The concept behind the technology draws on historical observations that patients with naturally occurring interatrial shunts experience milder symptoms of heart failure. By creating a controlled shunt, InterShunt aims to replicate these beneficial effects in a more predictable and manageable way. Their approach has been validated through extensive pre-clinical studies and early human trials, showing promising results in terms of safety and effectiveness.
InterShunt has received significant financial backing to support its development efforts. In January 2021, the company completed an equity financing round led by Solas BioVentures, which included contributions from several industry executives and Arsenal Capital Management. These funds are being used to advance the PAS-C system through the necessary clinical trials and regulatory approvals.
Learn more about InterShunt by visiting their website.